avermectin B(1)a (CID 6434889) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(15)
 
 
Inactive(7)
 
 
Inconclusive(18)
 
 
Unspecified(131)
 
 
Top Targets:
7TM GPCR Srx(12)
 
 
 
7TM GPCR Srsx(10)
 
 
 
p450(8)
 
 
NR LBD PPAR(5)
 
 
 
NR LBD ER(4)
 
 
 
BioAssay Types:
Confirmatory(25)
 
 
 
 
Literature(3)
 
 
 
Screening(2)
 
 
BioActivity Types:
IC50(116)
 
 
 
Potency(25)
 
 
 
 
EC50(2)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 163    Data Row: 171   Total Pages: 4   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID124963713]
IC50 0.132DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) [AID625268, Type: other]
View
2
[SID124963713]
IC50 0.87DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) [AID625196, Type: other]Adenosine receptor A [gi:1351831]
View
3
[SID124963713]
IC50 0.87DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) [AID625196, Type: other]Adenosine receptor A [gi:1351831]
View
4
[SID124963713]
EC50 4Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay [AID547622, Type: Literature]
View
5
[SID124963713]
IC50 6.119DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) [AID625252, Type: other]D(1A) dopamine receptor [gi:118228]
View
6
[SID124963713]
IC50 6.119DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) [AID625252, Type: other]D(1A) dopamine receptor [gi:118228]
View
7
[SID124963713]
IC50 6.119DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) [AID625252, Type: other]D(1A) dopamine receptor [gi:118228]
View
8
[SID124963713]
IC50 6.119DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) [AID625252, Type: other]D(1A) dopamine receptor [gi:118228]
View
9
[SID124963713]
EC50 12Cytotoxicity against BESM cells after 88 hrs by HTS assay [AID547621, Type: Literature]
View
10
[SID50113085]
Potency 12.5893qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling [AID588546, Type: confirmatory]retinoid X nuclear receptor alpha [Homo sapiens] [gi:325495497]
View
11
[SID50113085]
Potency 12.5893qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling [AID588546, Type: confirmatory]retinoid X nuclear receptor alpha [Homo sapiens] [gi:325495497]
View
12
[SID50113085]
Potency 12.5893qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling [AID588546, Type: confirmatory]retinoid X nuclear receptor alpha [Homo sapiens] [gi:325495497]
View
13
[SID144204847]
Potency 16.3601qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
14
[SID144204847]
Potency 16.3601qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
15
[SID144204847]
Potency 16.3601qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
16
[SID50113085]
 qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways [AID651838_1, Type: other]
View
17
[SID50113085]
 qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways [AID651838_2, Type: other]
View
18
[SID50113085]
 qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways [AID651838_3, Type: other]
View
19
[SID50113085]
 qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways [AID651838_4, Type: other]
View
20
[SID50113085]
 qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways [AID651838_5, Type: other]
View
21
[SID50113085]
 qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways [AID651838_6, Type: other]
View
22
[SID50113085]
 qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways [AID651838_7, Type: other]
View
23
[SID50113085]
 qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways [AID651838_8, Type: other]
View
24
[SID124963713]
 DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta) [AID625274, Type: other]
View
25
[SID124963713]
IC50 DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4) [AID625275, Type: other]
View
26
[SID124963713]
IC50 DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) [AID625172, Type: other]Progesterone receptor [gi:75071465]
View
27
[SID124963713]
IC50 DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) [AID625144, Type: other]Leukotriene C4 synthase [gi:239977155]
View
28
[SID124963713]
IC50 DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) [AID625193, Type: other]Acetylcholinesterase [gi:113037]
View
29
[SID124963713]
IC50 DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) [AID625194, Type: other]Adenosine receptor A [gi:231473]
View
30
[SID124963713]
IC50 DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) [AID625194, Type: other]Adenosine receptor A [gi:231473]
View
31
[SID124963713]
IC50 DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) [AID625194, Type: other]Adenosine receptor A [gi:231473]
View
32
[SID124963713]
IC50 DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) [AID625195, Type: other]Adenosine receptor A2 [gi:543740]
View
33
[SID124963713]
IC50 DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) [AID625195, Type: other]Adenosine receptor A2 [gi:543740]
View
34
[SID124963713]
IC50 DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) [AID625195, Type: other]Adenosine receptor A2 [gi:543740]
View
35
[SID124963713]
 Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells [AID547804, Type: Literature]
View
36
[SID124963713]
IC50 DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) [AID625158, Type: other]
View
37
[SID124963713]
 DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) [AID625164, Type: other]
View
38
[SID124963713]
IC50 DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625165, Type: other]
View
39
[SID124963713]
IC50 DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625166, Type: other]
View
40
[SID124963713]
 DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) [AID625169, Type: other]
View
41
[SID124963713]
IC50 DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) [AID625170, Type: other]
View
42
[SID124963713]
 DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) [AID625189, Type: other]
View
43
[SID124963713]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) [AID625190, Type: other]
View
44
[SID124963713]
IC50 DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) [AID625197, Type: other]
View
45
[SID124963713]
IC50 DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) [AID625210, Type: other]
View
46
[SID124963713]
 DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) [AID625211, Type: other]
View
47
[SID124963713]
IC50 DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) [AID625212, Type: other]
View
48
[SID124963713]
IC50 DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) [AID625215, Type: other]
View
49
[SID124963713]
IC50 DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) [AID625216, Type: other]
View
50
[SID124963713]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) [AID625219, Type: other]
View